Welcome to our dedicated page for Xencor news (Ticker: XNCR), a resource for investors and traders seeking the latest updates and insights on Xencor stock.
Xencor, Inc. (NASDAQ: XNCR) is a clinical-stage biopharmaceutical company developing engineered antibodies for cancer and autoimmune diseases, and its news flow reflects both internal pipeline progress and partner-driven milestones. The company regularly issues updates on its XmAb® drug candidates, including T-cell engaging bispecific antibodies and Fc-engineered antibodies that use its XmAb and Xtend™ technologies.
Investors following XNCR news can expect detailed announcements on clinical trial progress across oncology and autoimmune indications. Recent releases have covered Phase 1 and Phase 2 studies of programs such as XmAb819 for advanced clear cell renal cell carcinoma, XmAb541 for gynecologic and germ cell tumors, plamotamab for rheumatoid arthritis, XmAb657 for idiopathic inflammatory myopathies, and XmAb942 and XmAb412 for inflammatory bowel and other autoimmune diseases. These updates often include safety and efficacy summaries, dose-escalation status, and plans for pivotal or proof-of-concept studies.
Xencor’s news stream also features financial results and guidance, including quarterly earnings, cash and marketable securities levels, and commentary on how its balance sheet supports research and development plans. In addition, the company reports on intellectual property developments, such as U.S. patent issuances that extend royalty terms on Xtend-based antibodies like Ultomiris, and on collaboration milestones with partners including Amgen, Astellas, Incyte and Zenas Biopharma.
Corporate governance and strategic updates, such as board appointments and participation in investor conferences, are also common topics. For investors and analysts, the XNCR news page provides a centralized view of how Xencor’s XmAb technology platform is progressing in the clinic, how partnered programs are advancing, and how these activities translate into milestones, royalties and long-term development plans.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, announced participation in two upcoming investor conferences focused on oncology and healthcare.
- Guggenheim Healthcare Talks | 2021 Oncology Days: February 11-12, 2021, with a presentation on February 11 at 1:00 p.m. EST.
- 10th Annual SVB Leerink Global Healthcare Conference: February 22-26, 2021, with a presentation on February 24 at 3:00 p.m. EST.
Live webcasts will be available on the company's website, with replays for 30 days post-event.
Xencor (NASDAQ:XNCR) has entered a strategic research collaboration with MD Anderson Cancer Center to develop innovative CD3 bispecific antibody therapeutics aimed at cancer treatment. This partnership combines Xencor's XmAb® technology with MD Anderson's antibody research expertise. The collaboration includes preclinical development of undisclosed antibody candidates, with Xencor obtaining licensing options for potential new medicines. This initiative aims to advance antibody-based therapies that enhance immune responses against tumors, addressing an urgent need in cancer treatment.
Xencor, Inc. (NASDAQ:XNCR) has announced a research collaboration and license agreement with Janssen Biotech. This partnership focuses on developing XmAb bispecific antibodies targeting CD28 and a prostate tumor, aimed at treating prostate cancer. Xencor will receive an upfront payment of $50 million and potential future milestone payments and royalties on sales. Both companies will explore combination therapies using their respective drug candidate portfolios. The agreement is pending customary closing conditions, with expected completion by year-end.
Xencor, Inc. (NASDAQ:XNCR) reported updated data from a Phase 1 study of vibecotamab (XmAb®14045), a bispecific antibody targeting CD123 and CD3 in patients with relapsed or refractory acute myeloid leukemia (AML). Presenting at the 62nd ASH Annual Meeting, the results showed a 15% overall response rate with durable responses in some patients. The most common toxicity was mild-to-moderate cytokine release syndrome (CRS), affecting 61% of participants. Xencor's next steps include further development of vibecotamab, particularly in patient populations with minimal residual disease.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, will participate in three major conferences. The Jefferies Virtual London Healthcare Conference is scheduled for November 17-19, 2020, with a presentation on November 19 at 5:00 p.m. GMT. The SVB Leerink Oncology Day will occur on the same day. Additionally, the Piper Sandler 32nd Annual Virtual Healthcare Conference is set for November 30 - December 3, 2020, with presentation availability starting on November 23. Webcasts will be available on Xencor's website after the events.
Xencor (NASDAQ: XNCR) has entered a clinical collaboration with MorphoSys AG and Incyte to evaluate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma.
This partnership aims to accelerate the clinical development of plamotamab, which has shown promise in treating non-Hodgkin lymphoma. The Phase 1/2 study will be conducted in North America, Europe, and Asia-Pacific.
Xencor, Inc. (NASDAQ:XNCR) has presented new data from its preclinical XmAb bispecific antibody and IL-12-Fc cytokine programs at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). This includes advancements in CD28 bispecific antibodies designed to co-stimulate T cells targeting tumor cells. The company showcased two selective TGFβ inhibitors and IL-12-Fc fusions, showing improved anti-tumor activity and potential benefits over existing therapies. Xencor continues to advance its innovative monoclonal antibody technology aimed at treating cancer and autoimmune diseases.
Xencor, Inc. (NASDAQ:XNCR) announced that data from its Phase 1 dose-escalation study of vibecotamab will be presented at the 2020 ASH Annual Meeting. Vibecotamab is a bispecific antibody targeting CD123 and CD3, developed for treating relapsed/refractory acute myeloid leukemia (AML). Initial results indicate that patients with low disease burden and specific T-cell signatures may respond better to treatment. Toxicities were primarily mild-to-moderate, with cytokine release syndrome observed in 58% of patients. The study continues to optimize dosing and prepare for future trials.
Xencor, Inc. (NASDAQ: XNCR) will announce its third quarter 2020 financial results on November 5, 2020, after market close. Management will host a webcast and conference call at 4:30 p.m. ET to discuss these results and provide a corporate update. Investors can access the call via phone or through the company’s website. Xencor focuses on developing engineered monoclonal antibodies targeting cancer and autoimmune diseases, with 18 candidates currently in clinical development leveraging its proprietary XmAb® technology.
Xencor, Inc. (NASDAQ:XNCR) has announced four poster presentations at the virtual 35th Annual Meeting of the Society for Immunotherapy of Cancer, scheduled for November 9-14, 2020. The presentations will showcase updated results from the Phase 1 study of XmAb®20717, a PD-1 x CTLA-4 bispecific antibody targeting advanced solid tumors. New data on three preclinical-stage programs will also be presented. The poster session will occur from November 11-14, with access to the materials available via Xencor's website.